Exon 19 Deletion Association With Progression-Free Survival Compared To L858r Mutation At Exon 21 In Treatment With First-Line Egfr-Tkis: A Meta-Analysis Of Subgroup Data From Eight Phase Iii Randomized Controlled Trials.

8107 Background: The superior efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) compared with cytotoxic chemotherapy in patients harboring sensitive EGFR mutations has been extensively proved by a well-known series of eight phase III randomized controlled trials (RCT). However, the question of whether the efficacy of EGFR-TKIs differs between EGFR exon 19 deletions and exon 21 L858R mutations has not been statistically answered. Methods: Subgroup data on hazard ratio (HR) for progression free survival (PFS) in these RCTs were extracted and were synthesized based on random-effect model. Comparison of outcomes between specific mutations was estimated through indirect methods. All calculations were performed using STATA version 11.0. Results: A total of 7 randomized RCTs (IPASS, WJTOG3405, EUTRAC, OPTIMAL, LUXLUNG3, and LUXLUNG6, as well as NEJ002 being included in sensitivity analysis) involving 1489 patients with either 19 or 21 exon alteration receiving first-line EGFR-TK...